Related Experiment Video
Updated: Jun 13, 2026
10:03
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Biomarkers for diagnosis in thoracic aortic disease: PRO
1Cardiac Surgery, Yale School of Medicine, PO Box 208039, New Haven, CT 06520-8039, USA. donald.botta@yale.edu
Cardiology Clinics
|May 11, 2010
Summary
Identifying biomarkers for thoracic aortic aneurysm (TAA) is crucial for predicting rupture risk. This research reviews current and potential cellular, protein, and molecular markers to aid clinical decisions for TAA management.
Area of Science:
- Cardiovascular Medicine
- Biomarker Discovery
- Genetics and Molecular Biology
Background:
- Thoracic aortic aneurysm (TAA) complications are frequent, necessitating improved diagnostic and prognostic tools.
- Preemptive surgical repair of TAAs enhances survival rates.
- Clinical decisions for asymptomatic TAA repair hinge on balancing operative risk against aneurysm rupture risk.
Purpose of the Study:
- To highlight the critical need for identifying patients with thoracic aortic aneurysm (TAA) at high risk of rupture or dissection.
- To review existing clinical biomarkers and explore emerging cellular, protein, and molecular markers for TAA risk stratification.
Main Methods:
- Literature review of current clinical practices for TAA management.
- Exploration of cellular, protein, and molecular markers associated with TAA development and progression.
- Analysis of the potential clinical utility of identified biomarkers.
Main Results:
- Current clinical markers are insufficient for precise TAA rupture risk assessment.
- Emerging cellular, protein, and molecular markers show promise for improved risk stratification.
- A multi-level biomarker approach may enhance predictive accuracy for TAA events.
Conclusions:
- Accurate identification of TAA rupture risk is vital for optimizing surgical intervention timing.
- Further research into novel biomarkers at the cellular, protein, and molecular levels is essential.
- Development of advanced biomarkers will improve patient outcomes and clinical decision-making in TAA management.
Related Concept Videos
01:21Aneurysm II: Clinical Manifestations and Diagnostic Studies
Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
01:22Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:21Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...